 |
Zeba Khan is currently Executive Director and Head of U.S. Pricing, Pricing Strategy & Policy at Novartis Pharmaceuticals Corporation based in East Hanover, New Jersey, USA. She leads the development and implementation of pricing and contracting strategy for general medicines. Dr. Khan joined Novartis in January 2003 as Global Head of Pricing and Health Economics Strategy, CVM, working and living in Basel, Switzerland for three years prior to moving to the USA. Prior to joining Novartis, Dr. Khan was employed at GlaxoSmithKline, Research Triangle Park, North Carolina, USA, for six years in various leadership roles in health care management, managed markets and was Senior Health Outcomes Scientist in North America, Department of Medical Affairs, where she developed and implemented health economics and outcomes strategies to support market access. Prior to joining the pharmaceutical industry in 1997, Dr. Khan was a clinical pharmacist at University Hospital, University of Utah Health Sciences Center and Poison Center Specialist at the Intermountain Regional Poison Control Center, both based in Salt Lake City, Utah, USA.
Dr. Khan earned her pharmacy degree from the University of Utah and her MS and PhD in Pharmacy Administration, Pharmacoeconomics/Health Outcomes from The University of Texas at Austin. Over her 18-year career, she has gained both USA and global experience in strategic pricing and contracting, health economics, outcomes research, managed markets, health care management, and clinical pharmacy. She has authored/co-authored over 90 publications, patents, and podium/poster presentations.
Dr. Khan has been a member of ISPOR since 1996, and has served in many capacities, including membership on the ISPOR Vision 2005 Committee, ISPOR Fellowship Committee, ISPOR Awards Committee, and ISPOR Program/Planning Committee. Most recently, she serves as the Co-Chair of the ISPOR Short Course Committee and has served over 8 years as the ISPOR Student Network Faculty Advisor.
ISPOR has grown to become a strong, international organization in a short time. My vision is to evolve an organization that is sustainable in an ever changing environment. That evolution can only be accomplished through globalization, international growth, collaboration and teamwork locally, regionally, and globally. Given the industry challenges, ISPOR must be the leader in establishing guidelines/standards that foster better research, leading to better decision-making and improved patient care. We must also lead in developing and communicating health outcome and scientific information while fostering continued education and shaping the future. These challenges can be addressed by: 1) Strengthening educational activities, distance learning programs, and short courses by considering feasibility of certification, leveraging the ISPOR Educator’s Toolkit, tapping into the ISPOR Speaker’s Bureau, and reaching out to new groups in our discipline globally; 2) Empowering our task forces and work groups to advance the science, methods, interpretation, and their application; 3) Understanding payer needs since the economic evidence required for decision-making may vary depending on geography, regulations, and country-specific needs. ISPOR must reach out to decision-makers at all levels to build partnerships; 4) Supporting student initiatives to ensure student representation in all ISPOR committees. Since students are the future of ISPOR, they should be engaged early to develop future leaders and provide growth for the organization.
My professional experience in the USA and Europe and my active involvement with ISPOR has prepared me to see this vision through to realization. Since 2004, I have served as Co-Chair of the Short Course Committee which has focused on developing content, building new courses, and evaluating courses for quality assurance. As a result, attendance and the number of short courses have tripled since 1998. As the ISPOR Student Advisor, I am proud of the accomplishments of the Student Network. We have grown from 5 members in 1995 to over 400, comprising 15% of the ISPOR membership with 38 ISPOR Student Chapters in the USA, Canada, Europe, and Asia. I welcome the opportunity to work with you to continue to build a future ISPOR organization that is sustainable and recognizable across all scientific disciplines.
TOP |
